SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Septerna Selects SEP-204 as Development Candidate for Graves’ Disease and TED

Septerna also reports preclinical data at the 2026 American Thyroid Association Annual Meeting.

SEPN

Related stories